Is Vaxart, Inc. overvalued or undervalued?

As of 3 August 2023, the valuation grade for Vaxart, Inc. has moved from does not qualify to risky. The company is currently overvalued based on its financial metrics. Key ratios include a Price to Book Value of 2.03, an EV to Sales ratio of 1.22, and a troubling ROCE of -535.64%.
In comparison to peers, Vaxart's EV to EBITDA ratio stands at -1.09, while TScan Therapeutics, Inc. has a ratio of 0.5157, and Prelude Therapeutics, Inc. has a ratio of -0.0018, indicating Vaxart is underperforming relative to its industry counterparts. The stock has significantly lagged behind the S&P 500, with a year-to-date return of -41.85% compared to the index's 12.22%, highlighting its challenging position in the market.